Charles Russell Speechlys acts on Circle Property IPO
Charles Russell Speechlys is delighted to have acted for Circle Property Plc on their admission to the AIM market of the London Stock Exchange.
The AIM community continues to be an important focus for the firm, given AIM’s status as the pre-eminent market for smaller and mid- cap quoted companies. We continue to take an active role in supporting companies and their owners/investors in their growth cycle and regularly support clients on topical issues, such as our recent seminars on shareholder activism and the AGM season.
Circle Property is a Jersey incorporated company which specialises in regional UK property investment, development and management consultancy. Circle’s operations were established in the UK in 2002 with the intention of acquiring a portfolio of UK commercial properties for investment purposes. Upon admission, Circle Property owns a freehold and leasehold portfolio of 16 real estate assets independently valued at over £73 million. The Company’s aim is to build a portfolio of prime regional offices by adding value to under-utilised buildings, securing lettings swiftly and ahead of competition, thereby generating attractive initial yields. We hope to be alongside them through that process.
Speaking of the deal, Andrew Collins who led the team working with Circle Property has said, “We are pleased to have acted for Circle Property. They have huge ambition and we hope to continue to work with them to ensure they achieve their plans. ”
Speaking on behalf of Circle Property John Arnold, CEO has said “The successful completion of Circle’s IPO is a significant step forward in the evolution of the Company. We could not have done this without the breadth of expertise that Charles Russell Speechlys was able to provide. Their calm and personable approach to our placing was invaluable. ”
Andrew Collins was backed by a strong team involving Paul Arathoon, Amelly Kok and Sarah Mold.
News & Insights
ECM and Brexit: business as usual?
We consider how ECM could be affected by the UK's impending departure from the EU
Kiadis Pharma secures €20 million debt financing facility from Kreos Capital
Charles Russell Speechlys advises Kreos Capital V Ltd on additional growth capital investment of €20 million in Kiadis Pharma NV